<DOC>
	<DOCNO>NCT00306293</DOCNO>
	<brief_summary>Eligible subject randomize receive VALTREX 1g placebo daily 60 day two-way crossover study washout period 7 day .</brief_summary>
	<brief_title>VALTREX ( Valacyclovir ) Once Daily Viral Shedding In Subjects Newly Diagnosed With HSV-2</brief_title>
	<detailed_description />
	<mesh_term>Herpes Labialis</mesh_term>
	<mesh_term>Valacyclovir</mesh_term>
	<mesh_term>Acyclovir</mesh_term>
	<criteria>Subject overall general good health . If female , subject must : 1 . Nonchildbearing potential ( i.e. , physiologically incapable become pregnant , include female premenarchial postmenopausal surgically sterile ) ; 2 . Childbearing potential , must negative pregnancy test randomization , must compliant one following : Complete abstinence intercourse two week exposure study drug , throughout clinical trial , period 1 week study completion premature discontinuation study ( account elimination drug ) ; Have male partner confirm sterile prior female subject 's entry study sole sexual partner female subject ; Use contraceptive ( ) document failure rate le 1 % per year , include limited : implant levonorgestrel , use injectable progestogen , oral contraceptive ( either combine progestogen ) , intrauterine device ( IUD ) spermicide plus mechanical barrier ( condom/diaphragm ) . Subjects must newly diagnose first recognize episode genital herpes describe ( ) ( b ) ( See Appendix 3 ) : a.HSV2 seropositive screen , document clinical sign symptom consistent genital herpes screen within 4 month prior randomization b.HSV2 seronegative screen , AND HSV2 culture positive HSV2 PCR positive document clinical sign symptom consistent genital herpes screen within 4 month prior randomization . Subject must willing able provide write informed consent comply protocol . Subject know suspect immunocompromised ( e.g. , subject receive immunosuppressive therapy chemotherapy malignancy , seropositive HIV ) . Subject receive investigational drug 30 day prior randomization visit . Subject receive systemic antiviral immunomodulatory treatment . Subjects receive systemic antiherpetic treatment ( e.g. , valacyclovir , acyclovir , ganciclovir , famciclovir ) within 3 day start study drug , immunomodulatory treatment 30 day start study drug . Subject clinically significantly impaired renal function define creatinine clearance less 50ml/min ( calculate use CockcroftGault formula ) . Subjects history evidence decompensated liver disease , clinically significantly impaired hepatic function define ALT ( alanine transaminase ) level &gt; 3 time normal upper limit . Subject know hypersensitive valacyclovir , acyclovir , ganciclovir famciclovir . Subject malabsorption vomit syndrome gastrointestinal dysfunction may impair drug pharmacokinetics . Female subject contemplate pregnancy within duration study drug dose period . Female subject pregnant and/or nursing . Subject current alcohol drug abuse . Subjects receive suppressive ( daily ) therapy genital herpes prior randomization . Suppressive therapy define daily antiherpetic therapy least 4 week duration . Subjects history ocular HSV ( herpes simplex virus ) infection .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2016</verification_date>
	<keyword>Recurrent Genital Herpes</keyword>
</DOC>